Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears β-amyloid in a mouse model of Alzheimer disease

Journal of Clinical Investigation

Volumn 115, Issue 9, 2005, Pages 2423-2433

  Frenkel, Dan ^a   Maron, Ruth ^a   Burt, David S ^b   Weiner, Howard L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ID Biomedical Corporation of Quebec   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; GLATIRAMER; PROTEASOME;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; DISEASE MODEL; DRUG APPROVAL; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; IMMUNOTHERAPY; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIGENS, CD; BLOOD-BRAIN BARRIER; BRAIN; CYSTEINE ENDOPEPTIDASES; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; FEMALE; HUMANS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, TRANSGENIC; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; VACCINATION;

EID: 24644435506     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI23241     Document Type: Article

References (58)

1. Hardy, J., and Selkoe, D.J. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics [review]. Science. 297:353-356.
2. Hutton, M., and McGowan, E. 2004. Clearing tau pathology with abeta immunotherapy - reversible and irreversible stages revealed. Neuron. 43:293-294.
3. Busciglio, J., Lorenzo, A., Yeh, J., and Yankner, B.A. 1995. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron. 14:879-888.
4. Schenk, D., et al. 1999. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:173-177.
5. Weiner, H.L., et al. 2000. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48:567-579.
6. Morgan, D., et al. 2000. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:982-985.
7. Janus, C., et al. 2000. A beta peptide immunisation reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:979-982.
8. Dodart, J.C., et al. 2002. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5:452-457.
9. Bard, F., et al. 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:916-919.
10. DeMattos, R.B., et al. 2001. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98:8850-8855.
11. Solomon, B., Koppel, R., Hanan, E., and Katzav, T. 1996. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc. Natl. Acad. Sci. U. S. A. 93:452-455.
12. Solomon, B., Koppel, R., Frenkel, D., and Hanan-Aharon, E. 1997. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. U. S. A. 94:4109-4112.
13. Morgan, D., and Gitter, B.U. 2004. Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease. Neurobiol. Aging. 25:605-608.
14. Wilcock, D.M., et al. 2003. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 23:3745-3751.
15. Wilcock, D.M., et al. 2004. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol. Dis. 15:11-20.
16. Wilcock, D.M., et al. 2001. Number of Abeta inoculations in APP+PSI transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol. 20:731-736.
17. Frenkel, D., Balass, M., Katchalski-Katzir, E., and Solomon, B. 1999. High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation. J. Neuroimmunol. 95:136-142.
18. Das, P., et al. 2003. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/-knock-out mice. J. Neurosci. 23:8532-8538.
19. Orgogozo, J.M., et al. 2003. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 61:46-54.
20. Nicoll, J.A., et al. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9:448-452.
21. Hock, C., et al. 2003. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 38:547-554.
22. Fries, L.F., et al. 2001. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect. Immun. 69:4545-4553.
23. Johnson, K.P., et al. 1995. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 45:1268-1276.
24. Mucke, L., et al. 2000. High-level neuronal expression of a beta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaprotoxicity without plaque formation. J. Neurosci. 20:4050-4058.
25. Hsiao, K., et al. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274:99-102.
26. Aharoni, R., Teitelbaum, D., Sela, M., and Arnon, R. 1997. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 94:10821-10826.
27. Fatia, A.M., and Weiner, H.L. 2005. Oral tolerance. Immunol. Rev. 206:232-259.
28. Maton, R., et al. 2002. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation. 106:1708-1715.
29. Frenkel, D., et al. 2003. Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10-producing CD4+ T cells. J. Immunol. 171:6549-6555.
30. Plante, M., et al. 2001. Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. Vaccine. 20:218-225.
31. Jones, T., et al. 2004. Protollin: a novel adjuvant for intranasal vaccines. Vaccine. 22:3691-3697.
32. Wyss-Coray, T., et al. 2002. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. U. S. A. 99:10837-10842.
33. Buttini, M., et al. 2002. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein K depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J. Neurosci. 22:10539-10548.
34. Seabrook, T.J., et al. 2004. Species-specific immune response to immunization with human versus rodent A beta peptide. Neurobiol. Aging. 25:1141-1151.
35. Rogers, J., Strohmeyer, R., Kovelowski, C.J., and Li, R. 2002. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia. 40:260-269.
36. Kirk, J., Plumb, J., Mirakhur, M., and McQuaid, S. 2003. Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J. Pathol. 201:319-327.
37. Kipnis, J., et al. 2003. Therapeutic vaccination for closed head injury. J. Neurotrauma. 20:559-569.
38. Kipnis, J., et al. 2000. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc. Natl. Acad. Sci. U. S. A. 97:7446-7451.
39. Angelov, D.N., et al. 2003. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 100:4790-4795.
40. Benner, E.J., et al. 2004. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 101:9435-9440.
41. D'Andrea, M.R., Cole, G.M., and Ard, M.D. 2004. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol. Aging. 25:675-683.
42. Mitrasinovic, O.M., and Murphy, G.M., Jr. 2003. Microglial overexpression of the M-CSF receptor augments phagocytosis of opsonized Abeta. Neurobiol. Aging. 24:807-815.
43. Webster, S.D., et al. 2000. Complement component C1q modulates the phagocytosis of Abeta by microglia. Exp. Neurol. 161:127-138.
44. Bacskai, B.J., et al. 2002. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci 22:7873-7878.
45. Wyss-Coray, T., et al. 1997. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature. 389:603-606.
46. Wyss-Coray, T., et al. 2001. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. 7:612-618.
47. DiCarlo, G., Wilcock, D., Henderson, D., Gordon, M., and Morgan, D. 2001. Intrahippocampal LPS injections reduce Abeta load in APP+PSI transgenic mice. Neurobiol. Aging. 22:1007-1012.
48. Massari, P., et al. 2002. Cutting edge: immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent. J. Immunol. 168:1533-1537.
49. Kotilinek, L.A., et al. 2002. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22:6331-6335.
50. McGeer, P.L., and McGeer, E. 2003. Is there a future for vaccination as a treatment for Alzheimer's disease? Neurobiol. Aging. 24:391-395.
51. Weiner, H.L., and Selkoe, D.J. 2002. Inflammation and therapeutic vaccination in CNS diseases. Nature. 420:879-884.
52. Candy, S., and Walker, L. 2004. Toward modeling hemorrhagic and encephalitic complications of Alzheimer amyloid-beta vaccination in nonhuman primates. Curr. Opin. Immunol. 16:607-615.
53. Monsonego, A., et al. 2003. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 112:415-422. doi:10.1172/JCI200318104.
54. Monsonego, A., and Weiner, H.L. 2003. Immunotherapeutic approaches to Alzheimer's disease. Science. 302:834-838.
55. Akiyama, H., and McGeer, P.L. 2004. Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease. Nat. Med. 10:117-118; author reply 10:118-119.
56. Streit, W.J. 2004. Microglia and Alzheimer's disease pathogenesis. J. Neurosci. Res. 77:1-8.
57. Kuo, Y.M., et al. 2001. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 276:12991-12998.
58. Johnson-Wood, K., et al. 1997. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 94:1550-1555.